Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Serious outcomes
RCTs
RCT mortality
All outcomes

Feedback
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 sotrovimab studies
00.250.50.7511.251.51.752+GlaxoSmi.. (DB RCT)67%0.33 [0.01-8.16]death0/2911/292Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.01-8.16]0/2911/29267% improvementAll studies67%0.33 [0.01-8.16]0/2911/29267% improvement1 sotrovimab COVID-19 studyc19sv.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67Effect extraction pre-specifiedFavors sotrovimabFavors control 00.250.50.7511.251.51.752+GlaxoSmi.. (DB RCT)67%0.33 [0.01-8.16]0/2911/292Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.01-8.16]0/2911/29267% improvementAll studies67%0.33 [0.01-8.16]0/2911/29267% improvement1 sotrovimab COVID-19 mortality resultc19sv.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67Favors sotrovimabFavors control 00.250.50.7511.251.51.752+GlaxoSmi.. (DB RCT)67%0.33 [0.01-8.16]death0/2911/292Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.01-8.16]0/2911/29267% improvementAll studies67%0.33 [0.01-8.16]0/2911/29267% improvement1 sotrovimab COVID-19 serious outcomesc19sv.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67Effect extraction pre-specifiedFavors sotrovimabFavors control 00.250.50.7511.251.51.752+GlaxoSmi.. (DB RCT)67%0.33 [0.01-8.16]death0/2911/292Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.01-8.16]0/2911/29267% improvementAll studies67%0.33 [0.01-8.16]0/2911/29267% improvement1 sotrovimab COVID-19 Randomized Controlled Trialsc19sv.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67Effect extraction pre-specifiedFavors sotrovimabFavors control 00.250.50.7511.251.51.752+GlaxoSmi.. (DB RCT)67%0.33 [0.01-8.16]0/2911/292Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.01-8.16]0/2911/29267% improvementAll studies67%0.33 [0.01-8.16]0/2911/29267% improvement1 sotrovimab COVID-19 RCT mortality resultc19sv.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67Favors sotrovimabFavors control 00.250.50.7511.251.51.752+GlaxoSmi.. (DB RCT)67%0.33 [0.01-8.16]death0/2911/292Improvement, RR [CI]TreatmentControlGlaxoSmi.. (DB RCT)85%0.15 [0.04-0.56]progression3/29121/292sotrovimab COVID-19 outcomesc19sv.com Sep 25, 2021Favors sotrovimabFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit